Welcome to our dedicated page for Alexandria Real Estate Equities news (Ticker: ARE), a resource for investors and traders seeking the latest updates and insights on Alexandria Real Estate Equities stock.
Alexandria Real Estate Equities, Inc. (NYSE: ARE) is the largest office REIT specializing in collaborative science and technology campuses situated in urban innovation clusters. Established in 1994, Alexandria has pioneered this niche market, growing a formidable presence in top-tier locations like Greater Boston, San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. The company is renowned for its top-quality, diverse tenant base, which includes life science, agtech, and technology firms.
With a track record of developing Class A properties, Alexandria offers dynamic, collaborative environments that bolster tenant recruitment and retention, creativity, and productivity. Its urban campuses provide tenants with state-of-the-art facilities, including robust lab spaces and strategic amenities designed to enhance innovation and efficiency.
Recent achievements include a public offering of senior notes, with proceeds intended for general corporate purposes and strategic acquisitions, and notable investments from tenants like AstraZeneca for advanced cell therapy manufacturing. Additionally, Alexandria's partnerships extend to major biopharmaceutical companies like Takeda, underscoring its crucial role in supporting groundbreaking research and development.
Financially strong, Alexandria continues to generate substantial net cash from operations, allowing for regular dividend payouts and significant reinvestment into new projects. The company's ability to attract strategic capital through its venture platform underscores its influence in nurturing transformative life sciences and technology ventures.
Alexandria's significance in the REIT sector is further exemplified by its market capitalization of $33.1 billion and an asset base of 73.5 million SF across North America. The company's commitment to sustainability, innovation, and tenant success underscores its status as a leading, mission-driven life science REIT making a lasting positive impact on the world. For more details, visit www.are.com.
Alexandria Real Estate Equities (NYSE: ARE) declared a quarterly cash dividend of $1.15 per common share for Q4 2021, payable on January 14, 2022. This brings the total dividend for 2021 to $4.48 per share, a 6% increase from 2020. The dividend reflects the company's strong net cash from operating activities while maintaining a low 58% funds from operations payout ratio, allowing for reinvestment in development projects. Alexandria is dedicated to growth in life sciences and technology sectors.
Alexandria Real Estate Equities, Inc. (NYSE: ARE) will host a conference call and audio webcast on February 1, 2022, at 3:00 p.m. ET to discuss its fourth quarter and year-end 2021 operating and financial results. The results will be released after the market closes on January 31, 2022. Interested participants can join the call by dialing (833) 366-1125 (U.S.) or (412) 902-6738, or listen via the company’s website. A replay will be available from 5:00 p.m. ET on February 1 until February 8, 2022.
Alexandria Venture Investments, affiliated with Alexandria Real Estate Equities (ARE), has intensified its investments in the agrifoodtech sector, recognized as one of the top five U.S. investors in 2021 by AgFunder. The sector has seen growth from $8.9 billion in 2016 to $24 billion in early 2021. Alexandria aims to double its investment this year, focusing on companies innovating in sustainable agriculture and human health. The firm supports various companies, including GreenLight Biosciences and Bear Flag Robotics, further enhancing its portfolio.
On November 16, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced plans to enhance R&D and next-gen manufacturing in Research Triangle, N.C. The company is partnering with biotechnology firms and acquiring development sites to help these companies control their medicine quality and supply chains. Alexandria's recent acquisition includes 95 acres for biomanufacturing centers. They aim to foster integrated manufacturing capabilities, crucial for developing complex medicines. Alexandria's market cap stands at $38.6 billion, with a significant presence in major innovation hubs across North America.
On October 25, 2021, Alexandria Real Estate Equities (NYSE:ARE) announced its financial results for Q3 2021, showing total revenues of $547.8 million, a 0.5% increase from Q3 2020. Net income attributable to common stockholders rose to $101.3 million ($0.67 per share), reflecting strong demand for office and laboratory spaces. The company secured a 15-year lease with Moderna for a new HQ, marking its largest life science lease. Year-to-date leasing volume reached 5.4 million RSF, with a 39.4% rental rate increase. S&P upgraded its credit outlook to BBB+/Positive, emphasizing strong fundamentals.
On October 18, 2021, Alexandria Venture Investments, a part of Alexandria Real Estate Equities (NYSE: ARE), was named the most active biopharma corporate investor by new deal volume for the fourth consecutive year. The recognition is part of Silicon Valley Bank's Healthcare Investments and Exits: Mid-Year 2021 Report. Alexandria also ranked as the top new Series A investor in biopharma. The firm has a market capitalization of $36.3 billion and has invested in notable companies such as GRAIL and Thrive Earlier Detection, enhancing its role in advancing health science.
On September 30, 2021, Alexandria Real Estate Equities (NYSE: ARE) announced its collaboration with Moderna to develop a new 462,000 RSF headquarters and R&D facility at 325 Binney Street, Cambridge. This cutting-edge building, designed to be the most sustainable laboratory in Cambridge, aims for net-zero energy consumption and various environmental certifications. Construction is underway, with completion expected in 2023, supporting Moderna's growth in mRNA medicines. Alexandria has expanded its asset base to approximately 15 million square feet in Greater Boston, emphasizing its role in the life science ecosystem.
Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in
FAQ
What is the current stock price of Alexandria Real Estate Equities (ARE)?
What is the market cap of Alexandria Real Estate Equities (ARE)?
What does Alexandria Real Estate Equities, Inc. do?
Where are Alexandria Real Estate properties located?
Who are Alexandria's primary tenants?
What recent achievements has Alexandria Real Estate Equities accomplished?
What is Alexandria's financial condition?
How does Alexandria support innovation?
What is the market capitalization of Alexandria Real Estate Equities?
How does Alexandria contribute to sustainability?
What is Alexandria's venture platform?
Where can I find more information about Alexandria Real Estate Equities?
